Anti-infective Agents
18
0
0
14
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
3 terminated out of 18 trials
82.4%
-4.2% vs benchmark
17%
3 trials in Phase 3/4
21%
3 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (18)
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Neuroimmune Dysfunction in Alcohol Use Disorder
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Probiotics to Promote Intestinal Health
A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant
Compliance of Initial Empiric Antimicrobial Therapy
Safety, PK, and PD Study of IVRs Releasing TFV and LNG
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
Acceptability Study of Vaginal Films for HIV Prevention